Literature DB >> 16095644

Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein.

St Patrick Reid1, Washington B Cárdenas, Christopher F Basler.   

Abstract

We have identified a putative coiled-coil motif within the amino-terminal half of the ebolavirus VP35 protein. Cross-linking studies demonstrated the ability of VP35 to form trimers, consistent with the presence of a functional coiled-coil motif. VP35 mutants lacking the coiled-coil motif or possessing a mutation designed to disrupt coiled-coil function were defective in oligomerization, as deduced by co-immunoprecipitation studies. VP35 inhibits signaling that activates interferon regulatory factor 3 (IRF-3) and inhibits (IFN)-alpha/beta production. Experiments comparing the ability of VP35 mutants to block IFN responses demonstrated that the VP35 amino-terminus, which retains the putative coiled-coil motif, was unable to inhibit IFN responses, whereas the VP35 carboxy-terminus weakly inhibited the activation of IFN responses. IFN-antagonist function was restored when a heterologous trimerization motif was fused to the carboxy-terminal half of VP35, suggesting that an oligomerization function at the amino-terminus facilitates an "IFN-antagonist" function exerted by the carboxy-terminal half of VP35.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16095644      PMCID: PMC3955989          DOI: 10.1016/j.virol.2005.06.044

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  52 in total

Review 1.  Identification and characterization of viral antagonists of type I interferon in negative-strand RNA viruses.

Authors:  A García-Sastre
Journal:  Curr Top Microbiol Immunol       Date:  2004       Impact factor: 4.291

2.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

3.  Predicting coiled coils from protein sequences.

Authors:  A Lupas; M Van Dyke; J Stock
Journal:  Science       Date:  1991-05-24       Impact factor: 47.728

4.  Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes.

Authors:  E Mühlberger; B Lötfering; H D Klenk; S Becker
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

5.  Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1.

Authors:  B K Weaver; K P Kumar; N C Reich
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

6.  Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture.

Authors:  J Chou; E R Kern; R J Whitley; B Roizman
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

7.  Regulation of type I interferon gene expression by interferon regulatory factor-3.

Authors:  S L Schafer; R Lin; P A Moore; J Hiscott; P M Pitha
Journal:  J Biol Chem       Date:  1998-01-30       Impact factor: 5.157

8.  Paramyxovirus phosphoproteins form homotrimers as determined by an epitope dilution assay, via predicted coiled coils.

Authors:  J Curran; R Boeck; N Lin-Marq; A Lupas; D Kolakofsky
Journal:  Virology       Date:  1995-12-01       Impact factor: 3.616

9.  Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells.

Authors:  B H Harcourt; A Sanchez; M K Offermann
Journal:  Virology       Date:  1998-12-05       Impact factor: 3.616

10.  Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo.

Authors:  M G Wathelet; C H Lin; B S Parekh; L V Ronco; P M Howley; T Maniatis
Journal:  Mol Cell       Date:  1998-03       Impact factor: 17.970

View more
  60 in total

1.  The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation.

Authors:  Takeshi Noda; Larissa Kolesnikova; Stephan Becker; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

2.  Ebolavirus VP35 is a multifunctional virulence factor.

Authors:  Daisy W Leung; Kathleen C Prins; Christopher F Basler; Gaya K Amarasinghe
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

3.  The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR.

Authors:  Zongdi Feng; Melissa Cerveny; Zhipeng Yan; Bin He
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

4.  Ebola virus VP35 has novel NTPase and helicase-like activities.

Authors:  Ting Shu; Tianyu Gan; Peng Bai; Xiaotong Wang; Qi Qian; Hui Zhou; Qi Cheng; Yang Qiu; Lei Yin; Jin Zhong; Xi Zhou
Journal:  Nucleic Acids Res       Date:  2019-06-20       Impact factor: 16.971

5.  The Ebola virus ribonucleoprotein complex: a novel VP30-L interaction identified.

Authors:  A Groseth; J E Charton; M Sauerborn; F Feldmann; S M Jones; T Hoenen; H Feldmann
Journal:  Virus Res       Date:  2008-12-16       Impact factor: 3.303

6.  Expression, purification, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; Jay C Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-01-31

7.  Filovirus replication and transcription.

Authors:  Elke Mühlberger
Journal:  Future Virol       Date:  2007-03       Impact factor: 1.831

8.  Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression.

Authors:  Christopher R Kimberlin; Zachary A Bornholdt; Sheng Li; Virgil L Woods; Ian J MacRae; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

9.  The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Authors:  Martina Trunschke; Dominik Conrad; Sven Enterlein; Judith Olejnik; Kristina Brauburger; Elke Mühlberger
Journal:  Virology       Date:  2013-04-11       Impact factor: 3.616

10.  Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.

Authors:  Daisy W Leung; Kathleen C Prins; Dominika M Borek; Mina Farahbakhsh; JoAnn M Tufariello; Parameshwaran Ramanan; Jay C Nix; Luke A Helgeson; Zbyszek Otwinowski; Richard B Honzatko; Christopher F Basler; Gaya K Amarasinghe
Journal:  Nat Struct Mol Biol       Date:  2010-01-17       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.